Uses of FGF21 polypeptides comprising two or more mutations
AssigneeAmgen Inc.
InventorsEdward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
Life of this patent
Estimating the term…
Abstract
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
Claims4
A method of treating type 2 diabetes comprising administering to a human patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO:4, wherein the polypeptide comprises (a) an arginine residue at position 98 of SEQ ID NO:4;
- and (b) a glycine residue at position 171 of SEQ ID NO:4.
A method of reducing triglyceride levels in a patient comprising administering to a human patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO:4, wherein the polypeptide comprises (a) an arginine residue at position 98 of SEQ ID NO:4;
- and (b) a glycine residue at position 171 of SEQ ID NO:4.
A method of improving glucose tolerance in a patient comprising administering to a human patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO:4, wherein the polypeptide comprises (a) an arginine residue at position 98 of SEQ ID NO:4;
- and (b) a glycine residue at position 171 of SEQ ID NO:4.
A method of lowering insulin levels in a patient comprising administering to a human patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO:4, wherein the polypeptide comprises (a) an arginine residue at position 98 of SEQ ID NO:4;
- and (b) a glycine residue at position 171 of SEQ ID NO:4.
Dependencies are inferred from the claim text.